David A. Siegel Aadi Bioscience, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 15,300 shares of AADI stock, worth $28,611. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,300Holding current value
$28,611% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AADI
# of Institutions
68Shares Held
12MCall Options Held
9.4KPut Options Held
2.5K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.33 Million0.06% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.46 Million2.91% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.05 Million4.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.43 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC526KShares$984,2351.41% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $39.3M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...